Pfizer Inc (PFE) stock
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3047% above fair value
$28.47−0.39 (-1.35%)
Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%
Pfizer free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Pfizer's free cash flow for the twelve months ending Jun 28, 2026 was $10.99B, down 11.7% year over year. For fiscal 2025 it was $9.08B, down 7.7% from the year before. Over ten years it grew -3.7% a year on average. The highest annual figure on record is $29.87B in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.08B | -7.7% |
| FY2024 | Dec 31, 2024 | $9.84B | +105.2% |
| FY2023 | Dec 31, 2023 | $4.79B | -81.6% |
| FY2022 | Dec 31, 2022 | $26.03B | -12.8% |
| FY2021 | Dec 31, 2021 | $29.87B | +145.3% |
| FY2020 | Dec 31, 2020 | $12.18B | +15.5% |
| FY2019 | Dec 31, 2019 | $10.54B | -23.8% |
| FY2018 | Dec 31, 2018 | $13.84B | -6.8% |
| FY2017 | Dec 31, 2017 | $14.85B | +3.3% |
| FY2016 | Dec 31, 2016 | $14.37B | +8.1% |
| FY2015 | Dec 31, 2015 | $13.29B | -16.3% |
| FY2014 | Dec 31, 2014 | $15.89B | -3.6% |
| FY2013 | Dec 31, 2013 | $16.48B | +6.9% |
| FY2012 | Dec 31, 2012 | $15.42B | -17.0% |
| FY2011 | Dec 31, 2011 | $18.58B | +86.9% |
| FY2010 | Dec 31, 2010 | $9.94B | -35.4% |
| FY2009 | Dec 31, 2009 | $15.38B | -7.0% |
| FY2008 | Dec 31, 2008 | $16.54B | +44.1% |
| FY2007 | Dec 31, 2007 | $11.47B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 28, 2026 | $302.00M | – |
| Q1 FY2026 | Mar 29, 2026 | $2.18B | +23.0% |
| Q4 FY2025 | Dec 31, 2025 | $4.50B | -22.4% |
| Q3 FY2025 | Sep 28, 2025 | $4.00B | -34.0% |
| Q2 FY2025 | Jun 29, 2025 | -$1.20B | – |
| Q1 FY2025 | Mar 30, 2025 | $1.77B | +358.8% |
| Q4 FY2024 | Dec 31, 2024 | $5.80B | +38.3% |
| Q3 FY2024 | Sep 29, 2024 | $6.06B | +129.1% |
| Q2 FY2024 | Jun 30, 2024 | -$2.42B | – |
| Q1 FY2024 | Mar 31, 2024 | $386.00M | +428.8% |
| Q4 FY2023 | Dec 31, 2023 | $4.20B | -44.7% |
| Q3 FY2023 | Oct 1, 2023 | $2.65B | -48.5% |
| Q2 FY2023 | Jul 2, 2023 | -$2.12B | -128.6% |
| Q1 FY2023 | Apr 2, 2023 | $73.00M | -98.8% |
| Q4 FY2022 | Dec 31, 2022 | $7.58B | +54.3% |
| Q3 FY2022 | Oct 2, 2022 | $5.13B | -49.7% |
| Q2 FY2022 | Jul 3, 2022 | $7.42B | -31.1% |
| Q1 FY2022 | Apr 3, 2022 | $5.90B | +48.0% |
| Q4 FY2021 | Dec 31, 2021 | $4.91B | +2.1% |
| Q3 FY2021 | Oct 3, 2021 | $10.21B | +545.0% |
| Q2 FY2021 | Jul 4, 2021 | $10.76B | +247.4% |
| Q1 FY2021 | Apr 4, 2021 | $3.98B | +48.4% |
| Q4 FY2020 | Dec 31, 2020 | $4.81B | +49.1% |
| Q3 FY2020 | Sep 27, 2020 | $1.58B | -59.9% |
| Q2 FY2020 | Jun 28, 2020 | $3.10B | +45.3% |
| Q1 FY2020 | Mar 29, 2020 | $2.68B | +116.8% |
| Q4 FY2019 | Dec 31, 2019 | $3.23B | -21.5% |
| Q3 FY2019 | Sep 29, 2019 | $3.95B | -16.3% |
| Q2 FY2019 | Jun 30, 2019 | $2.13B | -37.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.24B | -22.5% |
| Q4 FY2018 | Dec 31, 2018 | $4.11B | -35.7% |
| Q3 FY2018 | Sep 30, 2018 | $4.71B | +6.2% |
| Q2 FY2018 | Jul 1, 2018 | $3.42B | +22.6% |
| Q1 FY2018 | Apr 1, 2018 | $1.60B | +30.3% |
| Q4 FY2017 | Dec 31, 2017 | $6.39B | +19.4% |
| Q3 FY2017 | Oct 1, 2017 | $4.44B | +3.1% |
| Q2 FY2017 | Jul 2, 2017 | $2.79B | – |
| Q1 FY2017 | Apr 2, 2017 | $1.23B | – |
| Q4 FY2016 | Dec 31, 2016 | $5.35B | – |
| Q3 FY2016 | Oct 2, 2016 | $4.31B | – |
See a number that looks wrong?